Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06494904 · ClinicalTrials.gov registry record · Phase 3
Standard Versus High Dose ED-Initiated Buprenorphine Induction
A Phase 3 study of Opioid Use Disorder, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 360
- Enrollment target
- 5
- Study locations
NCT06494904: Recruiting Phase 3 study of Opioid Use Disorder, sponsored by Yale University.
NCT06494904 is a Phase 3 study of Opioid Use Disorder that is actively recruiting participants, run by Yale University. The registered enrollment target is 360 participants, below the 4,655-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (92% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06494904, a Phase 3 study of Opioid Use Disorder, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 360 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is a multisite double-blind, double-dummy, randomized clinical trial enrolling ED patients with untreated moderate to severe opioid use disorder (OUD) to compare Standard Dose Induction (SDI) and High Dose Induction (HDI) on rates of participation in OUD treatment within 10 days post randomization, and opioid withdrawal symptoms, opioid craving, and use of illicit and non-prescribed drugs.
Primary Outcome
The proportion of patients in each of the two study arms participating in OUD treatment within 10 days after the study randomization
Conditions Studied
Interventions
- DRUG Buprenorphine
Study Locations (5)
California
- Highland Hospital - Oakland
- San Leandro Hospital - San Leandro
Maine
- Maine Medical Center - Portland
New Jersey
- Cooper University Hospital - Camden
Utah
- University of Utah Hospital - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2024-12-06 |
| Est. Completion | 2028-12 |
| Phase | Phase 3 |
What NCT06494904 shows while recruiting
NCT06494904 is an interventional study that assigns participants to a tested intervention. The registered 360 participants enrollment target is mid-sized for trials with a published cap, below the 4,655-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Buprenorphine is the first listed.
NCT06494904 lists 5 locations in 4 states (California, Maine, New Jersey).
Frequently Asked Questions
What is clinical trial NCT06494904 about?
NCT06494904 is a clinical study titled "Standard Versus High Dose ED-Initiated Buprenorphine Induction". This study is a multisite double-blind, double-dummy, randomized clinical trial enrolling ED patients with untreated moderate to severe opioid use disorder (OUD) to compare Standard Dose Induction (SDI) and High Dose Induction (HDI) on rates of participation in OUD treatment within 10 days post rand...
What is the current status of trial NCT06494904?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 360 participants. The study started on 2024-12-06. Estimated completion is 2028-12.
What conditions does trial NCT06494904 study?
This clinical trial studies the following conditions: Opioid Use Disorder.
What interventions are being tested in trial NCT06494904?
The interventions under investigation include: Buprenorphine (DRUG).
Who is sponsoring clinical trial NCT06494904?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06494904 being conducted?
This trial has 5 study locations across California, Maine, New Jersey, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06494904's enrollment target sits among peer trials
360 49th of 257 higher than 209 of 257 other Opioid Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Buprenorphine for Individuals in Jail
RECRUITING · Phase 3
-
Treating Polysubstance Use Using a Novel Digital Technology
RECRUITING · Phase 3
-
High Dose Buprenorphine (BUP) Induction in the Emergency Department (ED)
RECRUITING · Phase 3
-
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
RECRUITING · Phase 3
-
Transdermal Patch for BupRenorphine Induction DurinG PrEgnancy (Patch BRIDGE)
RECRUITING · Phase 3
-
Behavioral Pharmacological Examination of a Novel Buprenorphine Induction Method Among Individuals Who Use Fentanyl
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747836 · 360 participants
Ultrasound Analysis of Human Carpal Tunnel System
- NCT04089046 · 360 participants · NA
Telemedicine Enhanced Asthma Management - Uniting Providers for Teens (TEAM-UP for Teens)
- NCT04130503 · 360 participants · NA
The Recovery in Stroke Using PAP Study
- NCT04160000 · 360 participants · Phase 4
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI